Clinical Trials Awards and Advisory Committee
The Clinical Trials Awards and Advisory Committee (CTAAC) reviews and funds cancer clinical trials. CTAAC is responsible for the review, funding and management of awards for phase II studies testing aspects of feasibility or tolerability and/or efficacy, larger phase II and phase III therapeutic clinical trials and sample collections.
CTAAC reviews applications for funding or approval of late phase investigator-led studies. The former Feasibility Study Committee (FSC) was amalgamated into CTAAC in April 2008. CTAAC therefore also funds single or multi-centre prospective therapeutic, diagnostic or prevention phase II studies testing aspects of feasibility or tolerability and/or efficacy.
Additionally, CTAAC is now responsible for the review of prospective sample collections from clinical trials that are about to commence or are ongoing. Support will be provided for the collection of tumour blocks and bloods only, unless specific justification can be made by an applicant for the collection of additional sample types.
Applications submitted to CTAAC are assessed based on their scientific and technical merit, taking into consideration comments collected from expert peer reviewers. The Committee meets three times per year.
Terms of reference
See below for information on how to contact this Committee's secretariat and the available funding schemes.